George J Schreiber, 70Woodinville, WA

2002019, Dec 19, 2002

Feb 12, 2001

09/782504

Karl Hellstrom - Seattle WA, US
Kim Bruce - Seattle WA, US
George Schreiber - Seattle WA, US

A61K039/395
G01N033/574

424/183100, 424/142100, 435/007230

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab′)-LysPE40 and ChiBR96 Fab′-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

2004004, Mar 4, 2004

Jan 2, 2003

10/336672

Karl Hellstrom - Seattle WA, US
Kim Bruce - Seattle WA, US
George Schreiber - Redmond WA, US

Bristol-Myers Squibb Company - New York NY

A61K039/395
C12N005/06
C07K016/30

424/155100, 530/388800, 435/344000

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab′)-LysPE40 and ChiBR96 Fab′-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

2006001, Jan 26, 2006

Sep 9, 2005

11/223680

Karl Hellstrom - Seattle WA, US
Kim Bruce - Seattle WA, US
George Schreiber - Seattle WA, US

A61K 39/395
A61K 39/21

424178100, 424187100

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab′)fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab′)-LysPE40 and ChiBR96 Fab′-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

5491088, Feb 13, 1996

May 5, 1993

8/057444

Ingegerd Hellstrom - Seattle WA
Karl E. Hellstrom - Seattle WA
Kim F. Bruce - Seattle WA
George J. Schreiber - Redmond WA

Oncogen Limited Partnership

C12N 520
C07K 1630

43524024

The present invention relates to novel antibodies reactive with human carcinoma cells. More particularly, the antibodies of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; and a F(ab'). sub. 2 fragment of BR96. These antibodies are reactive with a cell membrane antigen on the surface of human carcinomas. The antibodies display a high degree of selectivity for carcinoma cells and possess the ability to mediate ADCC and CDC activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

5869045, Feb 9, 1999

Jun 2, 1995

8/459354

Karl Erik Hellstrom - Seattle WA
Kim Folger Bruce - Seattle WA
George J. Schreiber - Seattle WA

Bristol-Myers Squibb Company - New York NY

A61K 39395
C07K 1600

4241301

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab'). sub. 2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab'). sub. 2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

5980896, Nov 9, 1999

Jun 14, 1993

8/077253

Ingegerd Hellstrom - Seattle WA
Karl Erik Hellstrom - Seattle WA
Kim Folger Bruce - Seattle WA
George J. Schreiber - Redmond WA
Clay Siegall - Edmonds WA
Stephen McAndrew - Newtown PA

Bristol-Myers Squibb Company - Princeton NJ

A61K 38395
C07K 1630
C07K 1900
C12N 512

4241831

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab'). sub. 2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab'). sub. 2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

6020145, Feb 1, 2000

Nov 3, 1994

8/333840

Ingegerd Hellstrom - Seattle WA
Karl Erik Hellstrom - Seattle WA
Kim Folger Bruce - Seattle WA
George J. Schreiber - Seattle WA

Bristol-Myers Squibb Company - Princeton NJ

G01N 33574
G01N 3353
A61K 39395
C07K 1600

435 723

The present invention relates to novel antibodies, antibody fragments and antibody conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the antibodies, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal antibody, BR96; a human/murine chimeric antibody, ChiBR96; a F(ab'). sub. 2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab'). sub. 2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive with a cell membrane antigen on the surface of human carcinomas. The BR96 antibody and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the antibodies of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates. The antibodies also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.